ES2635131T3 - Inhibidores de la actividad de la proteína tirosina cinasa - Google Patents

Inhibidores de la actividad de la proteína tirosina cinasa Download PDF

Info

Publication number
ES2635131T3
ES2635131T3 ES08800252.2T ES08800252T ES2635131T3 ES 2635131 T3 ES2635131 T3 ES 2635131T3 ES 08800252 T ES08800252 T ES 08800252T ES 2635131 T3 ES2635131 T3 ES 2635131T3
Authority
ES
Spain
Prior art keywords
alkyl
group
pyridin
mmol
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08800252.2T
Other languages
English (en)
Spanish (es)
Inventor
Stephen William Claridge
Ljubomir Isakovic
Michael Mannion
Stéphane RAEPPEL
Oscar Mario Saavedra
Frédéric GAUDETTE
Lijie Zhan
Nancy Z. Zhou
Franck Raeppel
Robert Déziel
Arkadii Vaisburg
Tetsuyuki Uno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methylgene Inc
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Application granted granted Critical
Publication of ES2635131T3 publication Critical patent/ES2635131T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ES08800252.2T 2007-08-29 2008-08-28 Inhibidores de la actividad de la proteína tirosina cinasa Active ES2635131T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96867307P 2007-08-29 2007-08-29
US968673P 2007-08-29
PCT/CA2008/001538 WO2009026717A1 (en) 2007-08-29 2008-08-28 Inhibitors of protein tyrosine kinase activity

Publications (1)

Publication Number Publication Date
ES2635131T3 true ES2635131T3 (es) 2017-10-02

Family

ID=40386626

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08800252.2T Active ES2635131T3 (es) 2007-08-29 2008-08-28 Inhibidores de la actividad de la proteína tirosina cinasa

Country Status (19)

Country Link
US (3) US8404846B2 (enExample)
EP (1) EP2183254B1 (enExample)
JP (1) JP5656634B2 (enExample)
KR (1) KR101556269B1 (enExample)
CN (3) CN101932586A (enExample)
AR (1) AR068066A1 (enExample)
AU (1) AU2008293038B2 (enExample)
BR (1) BRPI0816064B8 (enExample)
CA (1) CA2697795C (enExample)
DK (1) DK2183254T3 (enExample)
ES (1) ES2635131T3 (enExample)
IL (1) IL204192A (enExample)
MX (1) MX2010002427A (enExample)
MY (1) MY156536A (enExample)
PL (1) PL2183254T3 (enExample)
RU (1) RU2495044C2 (enExample)
TW (1) TWI571468B (enExample)
WO (1) WO2009026717A1 (enExample)
ZA (1) ZA201001512B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009729A (es) * 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
AU2009303602B2 (en) * 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
MX2012002591A (es) 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2621482A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CN102827186A (zh) * 2011-06-16 2012-12-19 中国科学院上海药物研究所 一类吡啶并五元杂环衍生物及其制备方法和用途
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN103626761B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
WO2019077506A1 (en) 2017-10-17 2019-04-25 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
EP3762392B1 (en) 2018-03-08 2024-05-15 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
CN112566935B (zh) 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN109384799B (zh) * 2018-11-12 2020-07-14 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
JP2022554042A (ja) 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
WO2021050580A1 (en) * 2019-09-10 2021-03-18 Mirati Therapeutics, Inc. Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
WO2021098769A1 (en) * 2019-11-21 2021-05-27 Beigene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
EP4089095A4 (en) * 2020-01-07 2024-03-27 Medshine Discovery Inc. DEUTERATED THIENOPYRIDINE COMPOUND
EP4213844A4 (en) 2020-09-17 2024-11-20 Mirati Therapeutics, Inc. POLYTHERAPIES
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法
CN118846073B (zh) * 2024-06-25 2026-01-30 深圳海王医药科技研究院有限公司 一种酪氨酸激酶抑制剂的新应用
CN121281693B (zh) * 2025-12-08 2026-04-03 中国石油大学(华东) 一种构建稠油重组分平均分子结构的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
KR100799534B1 (ko) 2004-02-27 2008-01-31 에자이 알앤드디 매니지먼트 가부시키가이샤 신규 피리딘 유도체 및 피리미딘 유도체(1)
CN1960725A (zh) * 2004-03-15 2007-05-09 Ptc医疗公司 用于抑制血管发生的四环咔啉衍生物
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1781664B1 (en) 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008041053A2 (en) * 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
MX2007014617A (es) 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
US20100016307A1 (en) 2006-10-27 2010-01-21 Toshihiro Hamajima Novel compounds
MX2012012031A (es) * 2010-04-16 2012-12-17 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos.

Also Published As

Publication number Publication date
EP2183254A1 (en) 2010-05-12
PL2183254T3 (pl) 2017-10-31
CA2697795A1 (en) 2009-03-05
JP2010536887A (ja) 2010-12-02
IL204192A (en) 2016-08-31
CN105777776A (zh) 2016-07-20
RU2010111729A (ru) 2011-10-10
CN101932586A (zh) 2010-12-29
MX2010002427A (es) 2010-03-30
CN109970759B (zh) 2026-08-04
US8389541B2 (en) 2013-03-05
AR068066A1 (es) 2009-11-04
BRPI0816064B1 (pt) 2020-01-28
BRPI0816064B8 (pt) 2021-05-25
US20130165477A1 (en) 2013-06-27
DK2183254T3 (en) 2017-09-11
KR20100075873A (ko) 2010-07-05
AU2008293038A1 (en) 2009-03-05
RU2495044C2 (ru) 2013-10-10
ZA201001512B (en) 2010-11-24
US8846927B2 (en) 2014-09-30
TW200914458A (en) 2009-04-01
CN105777776B (zh) 2021-06-08
US20090264440A1 (en) 2009-10-22
US20120108628A1 (en) 2012-05-03
BRPI0816064A2 (pt) 2015-03-31
MY156536A (en) 2016-02-26
CA2697795C (en) 2016-08-16
WO2009026717A1 (en) 2009-03-05
EP2183254A4 (en) 2011-09-28
TWI571468B (zh) 2017-02-21
US8404846B2 (en) 2013-03-26
JP5656634B2 (ja) 2015-01-21
EP2183254B1 (en) 2017-06-21
AU2008293038B2 (en) 2013-08-29
KR101556269B1 (ko) 2015-09-30
CN109970759A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
DK2183254T3 (en) INHIBITORS OF PROTEINTYROSINKINASE ACTIVITY
US8729268B2 (en) Inhibitors of protein tyrosine kinase activity
HK1139407B (en) Inhibitors of protein tyrosine kinase activity
HK1139407A (en) Inhibitors of protein tyrosine kinase activity
HK1155977A (en) Inhibitors of protein tyrosine kinase activity